SCHEMBL5886929

SCHEMBL5886929

CC1=C(c2ccc(C)cc2)[CH]CC=C1c1ccc(Br)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
GAA P10253 3/20 0.37
HTR2C P28335 2/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
ESR1 P03372 1/20 0.32
MAOB P27338 1/20 0.32
NPC1 O15118 1/20 0.32
APP P05067 1/20 0.32
RAB9A P51151 1/20 0.32
PAX8 Q06710 1/20 0.32
MGAM O43451 2/20 0.31
SI P14410 2/20 0.31
MGAM2 Q2M2H8 2/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4009121 0.93 ALDH1A1 (0.33) ALDH1A1MEN1KMT2AMAPT
SCHEMBL5887164 0.81 ALDH1A1 (0.35) ALDH1A1GAAPAX8MAPT
SCHEMBL4799356 0.80 ALDH1A1 (0.34) ALDH1A1
SCHEMBL5887415 0.78 AHR (0.38) ALDH1A1GAAMEN1HTTKMT2A
SCHEMBL5887388 0.76 BACE1 (0.42) ALDH1A1GAAMEN1CYP3A4KMT2A
SCHEMBL4007569 0.72 ACHE (0.33) KMT2ANPC1RAB9A
SCHEMBL4811189 0.71 PTGS2 (0.38) ALDH1A1MEN1CYP2C19KMT2ARAB9A
SCHEMBL5887245 0.71 AR (0.31)
SCHEMBL5887317 0.70 ALOX5 (0.39) GAAMEN1KMT2ANPC1RAB9A
SCHEMBL260551 0.70 ALDH1A1 (0.81) ALDH1A1GAAMEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R ALDH1A1 1572/4885GAA 3931/4885HTR2C 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.